Palmitoylethanolamide for ulcerative colitis
Part of Digestive system clinical trials.
This study tests whether adding palmitoylethanolamide (a natural compound that may help reduce inflammation) to standard treatment can improve symptoms for people with active mild-to-moderate ulcerative colitis who are not responding well to current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ulcerative colitis (confirmed by endoscopy)
- Your disease must be active but mild to moderate, with a symptom score between 5 and 12
- You must have taken 5-ASA medications (like mesalamine) and they didn't work well enough
- You must also be taking corticosteroids along with 5-ASA medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This study tests whether a new treatment made from stem cell particles (called exosomes) can help calm moderate-to-severe ulcerative colitis when standard medicines haven't worked well enough. The treatment is given directly into the vein or under the skin, and the goal is to reduce symptoms and inflammation in the colon.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.